Wed., Nov. 18, 2020 | 10:00-11:15 a.m. CT | Live MBHB Webinar via WebEx
Since the creation of AIA Trial Proceedings in 2012, parties have filed more than 11,500 petitions to the Patent Trial and Appeal Board (“PTAB”). Today, these proceedings and the PTAB are a significant aspect of every major patent litigation. Yet, the contours of these proceedings continue to change. Four key topics should be at the forefront of every PTAB practitioner’s renewed focus this year:
First, the PTAB is increasingly using its discretion to deny institution of AIA Trial Proceedings. The PTAB’s discretionary denials, however, are based on multi-factor tests that differ from the PTAB’s typical standard for institution—whether the petitioner has shown a likelihood that a claim is unpatentable. Litigants have started to challenge the PTAB’s discretionary denials in the courts, including in an APA action in the U.S. District Court for the Northern District of California and in a mandamus petition the U.S. Court of Appeals for the Federal Circuit. Still others have urged Congress to take action.
Second, despite the PTAB’s new motion to amend pilot program, where patent owners can receive preliminary guidance from the PTAB on these motions and revise them, patent owners are filing less motions to amend. Federal Circuit case law on motions to amend is evolving as well. This year, the Federal Circuit ruled that the PTAB itself may raise new grounds against proposed substitute claims in a motion to amend. And the Court recently ruled that proposed substitute claims can be challenged on § 101 grounds.
Third, there is yet another constitutional challenge to AIA Trial Proceedings pending at the Supreme Court. In Arthrex v. Smith & Nephew, the issue is whether administrative patent judges (“APJs”) were properly appointed to the PTAB. And if not, what is the remedy (e.g., should the cases ripe for Arthrex challenges (and others) be affirmed, vacated and remanded, reversed, some combination of the three)? Either way, Arthrex has left a wake of uncertainty in many PTAB cases and the Supreme Court has scheduled its first conference on the Arthrex petitions for a writ of certiorari at the end of September.
Fourth, the Supreme Court also held this year in Thryv v. Click-to-Call that the PTAB’s time bar decisions are not reviewable. The Court’s holding in Thryv seemingly shut the door on judicial review of virtually all institution issues. Yet, in Facebook v. Windy City, the Federal Circuit recently ruled that the PTAB’s joinder decisions are reviewable because they are separate and subsequent decisions to institution decisions.
MBHB partners James Lovsin and George “Trey” Lyons, III will take a look at these topics and more and the impact they have on AIA Trial Proceedings, including:
Presenter(s): MBHB attorney(s) James Lovsin and George “Trey” Lyons, III
While there is no fee to participate, all attendees must register in advance and, in order to receive MCLE credit, must participate online and individually. Register online here
All registrants will receive an email confirmation and details for online participation.
MCLE credit is pending for the states of California, Illinois, New Jersey,* New York,* North Carolina and Virginia (*via reciprocity).
McDonnell Boehnen Hulbert & Berghoff LLP is committed to educating clients and friends of the firm with respect to significant developments and trends in the areas of intellectual property law.